GLCP-092-1

GLCP-092-1 is a small molecule drug candidate currently in development by **Galenicap**, a Swiss biotechnology company specializing in treatments for central nervous system (CNS) disorders. The compound is specifically targeted toward **post-stroke apathy** and **post-stroke aphasia**, two common and debilitating consequences of stroke that significantly hinder neurorehabilitation and patient recovery. While the precise mechanism of action and molecular target for GLCP-092-1 have not been publicly detailed in the company's high-level pipeline disclosures, the program is part of Galenicap's broader effort to utilize small molecule chemistry to improve functional outcomes in patients with neurological deficits. The drug is intended to address the lack of approved pharmacological therapies for these specific post-stroke conditions.

Other names

GLCP-092-1GLCP092-1GLCP 092-1